Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw an uptick in trading volume on Tuesday . 1,341,034 shares were traded during mid-day trading, an increase of 639% from the previous session’s volume of 181,365 shares.The stock last traded at $0.98 and had previously closed at $0.72.

Several brokerages recently issued reports on AST. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright set a $11.00 price objective on Asterias Biotherapeutics and gave the stock a “buy” rating in a report on Tuesday, October 9th.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its earnings results on Friday, November 9th. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.02. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.11 million.

A number of hedge funds have recently bought and sold shares of AST. Millennium Management LLC purchased a new stake in shares of Asterias Biotherapeutics in the second quarter worth about $663,000. Renaissance Technologies LLC boosted its position in shares of Asterias Biotherapeutics by 78.0% in the third quarter. Renaissance Technologies LLC now owns 187,100 shares of the biotechnology company’s stock worth $243,000 after buying an additional 82,000 shares during the period. Finally, Paloma Partners Management Co purchased a new stake in shares of Asterias Biotherapeutics in the second quarter worth about $194,000.

ILLEGAL ACTIVITY NOTICE: “Asterias Biotherapeutics (AST) Sees Strong Trading Volume” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at

Asterias Biotherapeutics Company Profile (NYSEAMERICAN:AST)

Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.

Featured Story: Investing in Growth Stocks

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with's FREE daily email newsletter.